XRF.AX — Equity Research Report

XRF Scientific Ltd

ASX: XRF.AX | Scientific Instruments & Materials | Method B

A$2.06

Last close (31 Dec 2025)

Report date: 9 April 2026

Market Cap

A$294.6M

A$284.9M

P/E (TTM)

27.7×

EV/EBITDA

16.7×

FCF/EV

3.6%

ROIC (TTM)

21.0%

Div Yield

2.2%

52W Range

$1.18–$2.06

Section 1: Business Overview

XRF Scientific is a Perth-headquartered manufacturer and distributor of sample preparation equipment, consumables, and precious metals products for the global mining laboratory industry. The business has been operating for over 35 years and has quietly compounded into a niche industrial gem — one of those companies that operates out of the spotlight but dominates a specific corner of the mining services ecosystem.

The core value proposition is simple: when miners need to analyse the chemical composition of rock samples (XRF analysis), XRF Scientific provides the fusion fluxes, crucibles, platinum-group metal labware, and automated fusion machines that make that analysis possible. The consumables side in particular has excellent recurring revenue characteristics — customers need fresh flux and new crucibles every time they run a sample.

The group operates across three segments. Capital Equipment (lab fusion machines, automated sample prep) generated ~A$22.3M TTM revenue and is the highest-growth segment. Precious Metals (platinum, iridium, and rhodium labware used at extreme temperatures) contributed ~A$21.4M. Consumables (fusion fluxes, borate chemicals, sample prep supplies) added ~A$18.1M and carries the best margins — this segment behaves almost like a subscription business given the repeat purchase cycle.

Geographically, Australia dominates (~67%), with Europe (~15%) and Canada (~18%) providing meaningful international diversification. The growing international footprint reduces dependence on the domestic Australian mining cycle, which can be lumpy.

Segment Revenue (TTM, A$M)

Segment	TTM Rev (A$M)	% of Total	TTM Pre-Tax Profit (A$M)	Character
Capital Equipment	22.3	36%	4.5	Capex-driven, lumpy order flow
Precious Metals	21.4	34%	4.4	PGM price exposure; durable demand
Consumables	18.1	29%	6.6	Recurring, high-margin, subscription-like
Eliminations/Corp	0.3	1%	(0.4)	Intercompany eliminations
Total	62.1	100%	15.1

Geographic Revenue (FY2025, A$M)

Region	Revenue (A$M)	% of Total
Australia	~40.0	~67%
Canada	~10.7	~18%
Europe	~8.8	~15%
Total	59.5	100%

Section 2: Financial Performance

The financials over the past five years tell a compelling story of disciplined growth. Revenue grew from A$31.3M in FY2021 to A$62.1M on a TTM basis — effectively doubling in four years. FY2023 was the standout year (+38.2%) as mining activity surged post-COVID; growth has since normalised into the mid-single digits, which is a more sustainable pace. Importantly, margins have expanded throughout this growth phase, a hallmark of genuine competitive advantage. Gross margin has climbed from 44.1% in FY2021 to 48.9% TTM, driven by the higher-margin consumables mix and pricing power.

The balance sheet is pristine. XRF carries A$12.1M in cash, just A$2.4M of total debt (mostly lease liabilities), and generates consistent positive FCF. The FY2022 FCF dip to A$2.6M was a working-capital catch-up during the rapid post-COVID revenue ramp; underlying earnings quality was fine.

Income Statement Summary (AUD Millions)

Metric	FY2021	FY2022	FY2023	FY2024	FY2025	TTM
Revenue	31.3	40.0	55.3	60.1	59.5	62.1
Gross Profit	13.8	17.3	24.1	27.6	28.8	30.4
EBITDA	7.2	8.9	14.1	16.0	16.5	17.1
EBIT	6.0	8.2	12.7	13.8	14.9	15.4
NPAT	5.1	6.1	7.7	8.9	10.4	10.6
Revenue Growth	—	+27.7%	+38.2%	+8.7%	−1.0%	+4.4%

Margin Trend (%)

Margin	FY2021	FY2022	FY2023	FY2024	FY2025	TTM
Gross Margin	44.1%	43.3%	43.6%	46.0%	48.4%	48.9%
EBITDA Margin	23.0%	22.3%	25.5%	26.6%	27.8%	27.5%
EBIT Margin	19.0%	20.6%	23.1%	22.9%	25.0%	24.8%
Net Margin	16.4%	15.2%	13.9%	14.8%	17.5%	17.1%
FCF Margin	12.4%	6.6%	13.6%	10.7%	15.0%	16.7%

Commentary: The sustained GP margin expansion from 44% to 49% is the key financial story. This isn't accidental — it reflects a deliberate shift toward higher-value consumables and better pricing. FCF conversion is strong and improving, with TTM FCF margin hitting 16.7%.

Balance Sheet Snapshot (Dec 2025, A$M)

Cash & Equivalents

A$12.1M

Net cash position: A$9.7M

Total Debt (incl. leases)

A$2.4M

Virtually debt-free

Common Equity

A$61.4M

Goodwill: A$15.8M

Total Assets

A$70.0M

Inventory: A$17.9M (25.5%)

Cash Flow Summary (AUD Millions)

Item	FY2021	FY2022	FY2023	FY2024	FY2025	TTM
Operating Cash Flow	4.5	3.2	8.3	8.1	10.2	12.1
Capex	(0.7)	(0.5)	(0.8)	(1.6)	(1.3)	(1.8)
Free Cash Flow	3.9	2.6	7.5	6.5	8.9	10.4
Dividends Paid	(1.9)	(2.7)	(3.6)	(4.1)	(4.1)	(6.4)

Commentary: Capex requirements are minimal relative to earnings — XRF is a capital-light business with low physical asset intensity. FY2022 OCF weakness was a working-capital timing issue, not a structural problem. Dividends have grown steadily from A$1.9M to A$6.4M TTM, a 3.4× increase over four years.

Section 3: Valuation — Enterprise DCF

WACC Build-Up

Input	Value	Notes
Risk-free rate (Rf)	4.35%	10-year Australian Government Bond yield
Beta (β)	0.85	Defensive-industrial; below-market volatility
Market Risk Premium (MRP)	6.0%	Standard Australian MRP
Cost of Equity (ke)	9.45%	Rf + β × MRP = 4.35 + 0.85 × 6.0
Cost of Debt (kd)	5.50%	Estimated from interest expense / avg debt
Tax rate	30.0%	Australian corporate rate
Equity weight (E/V)	99.2%	A$294.6M equity vs A$2.4M debt
Debt weight (D/V)	0.8%	Effectively zero leverage
WACC	9.40%	Dominated entirely by cost of equity

DCF Assumptions — Scenario Inputs

Assumption	Bear	Base	Bull
Revenue growth (Yr 1–3)	4%, 4%, 3%	8%, 8%, 7%	12%, 11%, 10%
Revenue growth (Yr 4–5)	3%, 2%	6%, 5%	9%, 8%
FCF Margin (normalised)	14.0%	17.0%	19.0%
Terminal growth rate (g)	1.5%	2.5%	3.0%
WACC	10.9%	9.4%	8.4%
RONIC	14.0%	18.0%	20.0%

Scenario Pricing

Bear Case

A$0.72

−65% vs market

Base Case

A$1.25

−39% vs market

Bull Case

A$1.94

−6% vs market

Market Price

A$2.06

Above all DCF cases

Commentary: The current market price of A$2.06 lies above every DCF scenario I can credibly construct, including the bull case at A$1.94. That's a notable signal. The terminal value represents 62–77% of total EV depending on scenario — meaning a significant portion of today's price is a bet on very long-term performance. To justify A$2.06 on fundamentals alone, you'd need WACC of ~7.4% AND terminal growth of ~4.0%, which is an optimistic combination for an Australian micro/small-cap industrial.

That said, I want to be honest: XRF's track record warrants a premium. The business has compounded reliably for a decade. The risk here isn't quality — it's price.

DCF Sensitivity Table — Per Share Equity Value (A$)

Rows = Terminal Growth Rate | Columns = WACC | Blue cell = base case

g \ WACC	7.4%	8.4%	9.4%	10.4%	11.4%
1.0%	1.50	1.31	1.16	1.04	0.95
1.5%	1.57	1.35	1.19	1.06	0.96
2.0%	1.64	1.39	1.22	1.08	0.97
2.5%	1.73	1.45	1.25	1.10	0.99
3.0%	1.83	1.51	1.29	1.13	1.01
3.5%	1.97	1.59	1.34	1.16	1.03
4.0%	2.14	1.68	1.39	1.20	1.05

Current price of A$2.06 is only justified at WACC ≤7.4% with terminal growth of ≥4.0% — a very narrow slice of the sensitivity space.

Section 4: Valuation — Economic Profit

Economic profit is my preferred sanity check on any DCF valuation. If a business consistently earns returns above its cost of capital, it genuinely creates value for shareholders — and that value should compound over time. XRF's numbers here are excellent.

Metric	FY2021	FY2022	FY2023	FY2024	FY2025	TTM
NOPAT (A$M)	4.17	5.76	8.92	9.63	10.40	10.75
Avg Invested Capital (A$M)	32.2	38.5	43.9	48.5	51.0	51.3
ROIC (%)	13.0%	15.0%	20.3%	19.9%	20.4%	21.0%
WACC (%)	9.4%	9.4%	9.4%	9.4%	9.4%	9.4%
ROIC − WACC Spread (pp)	+3.6	+5.6	+10.9	+10.5	+11.0	+11.6
Economic Profit (A$M)	1.16	2.16	4.79	5.09	5.61	5.93

Commentary: The ROIC-WACC spread has widened materially over five years — from a modest +3.6pp in FY2021 to +11.6pp TTM. This is exceptional for a small-cap Australian industrial. Annual economic profit of A$5.9M means the business genuinely creates value at roughly A$5–6M per year above its cost of capital. The trajectory is what matters: this spread has been consistent and widening, not a one-year anomaly. If XRF can sustain this spread, the business is worth holding through multiple cycles. The market clearly understands this — which is why it's priced at a significant premium to book.

Section 5: Valuation Summary — Football Field

Commentary: Every valuation methodology I've run produces a range below the current market price of A$2.06. The DCF bull case at A$1.94 is the closest — a mere 6% below market — but relies on optimistic assumptions across revenue growth, FCF margin, and terminal rate. The market is effectively paying a significant growth premium over and above what the financials can currently justify on a standalone DCF. This isn't necessarily wrong — quality businesses often trade at premiums for good reason — but it does mean upside from here is limited unless XRF meaningfully surprises to the upside.

Section 6: Savings Account Test (FCF/EV)

If you deposited A$284.9M (the Enterprise Value) into XRF Scientific, you'd earn:

3.6% per annum

In free cash flow terms. That's your 'interest rate' on the business.

Benchmark	Rate	vs XRF FCF/EV (3.6%)
RBA Cash Rate	4.10%	▼ XRF pays less
12-month Term Deposit	~5.0%	▼ XRF pays less
ASX 200 Earnings Yield	~5.5%	▼ XRF pays less
Risk Threshold (WACC)	9.4%	▼ XRF pays less

Commentary: XRF fails the Savings Account Test against every benchmark — you can earn more depositing money in a term deposit than you'd earn in FCF yield on today's enterprise value. This is the mathematical signature of a growth stock: the market is paying up today for expected future cash flows, not for current yield. That's a legitimate investment thesis if the growth materialises. But it does mean the margin of safety is thin at current prices. An investor buying at A$2.06 is making a bet on continued 8%+ revenue growth and margin expansion — the FCF doesn't show up in yield today.

Section 7: Allen/Plato Red Flags Assessment

FLAGS

WATCHES

CLEARS

Category	Status	Detail
1. Negative Operating Cash Flow	CLEAR	OCF positive every period; TTM A$12.1M, strong trajectory
2. Earnings-to-Cash-Flow Divergence	CLEAR	OCF/NPAT TTM = 1.14×; healthy conversion; no accruals concern
3. Excessive Debt (ND/EBITDA > 3×)	CLEAR	Net cash A$9.7M; Net Debt/EBITDA = −0.57× (net cash!)
4. Insider Selling	FLAG	Director Brown sold 1M shares at A$0.87 (May 2024) and 1M shares at A$1.39 (Sep 2025) — significant disposals at prices well below current. Partly offset by Stazzonelli on-market purchases.
5. Executive Remuneration	WATCH	No remuneration data extracted. Small-cap boards can exhibit pay-for-tenure tendencies; warrants direct review of annual report.
6. Corporate Governance	WATCH	Small board (4 directors). Chairman Grimwade has served for many years — board tenure and independence warrants monitoring.
7. Related Party Transactions	CLEAR	No material related-party transactions identified in available data
8. Auditor Quality	CLEAR	Grant Thornton (mid-tier, not Big 4) — noting as clean for this size company; standard for ASX small-cap
9. Aggressive Growth Expectations	WATCH	Market price implies growth assumptions that exceed all DCF base cases. Price is pricing in substantial optimism vs historical earnings.
10. High Beta (>1.5)	CLEAR	Beta estimated at 0.85; below-market volatility despite mining exposure
11. Non-Standard Performance Metrics	CLEAR	GAAP-only reporting; minimal use of adjusted/normalised metrics; clean presentation
12. Overstated Receivables/Inventory	CLEAR	Receivables/Revenue stable at ~14%; inventory turns reasonable for manufacturing. Inventory A$17.9M vs revenue A$62.1M = 0.29 turns, consistent with prior periods.

⚠️ CAUTION — 4 Flags + Watches (1 Flag, 3 Watches)

The main flag is Director Brown's two large sell transactions. This doesn't necessarily mean the business is in trouble — directors sell for many reasons — but at these valuation multiples, it's a yellow flag worth noting. The board tenure and governance watch is a standard small-cap concern. Overall this is a relatively clean quality company; the watches are structural, not crisis-level.

Section 8: Earnings at Risk & Economic Capital

These two metrics sit at the intersection of risk management and capital adequacy, applied here in the context of a non-financial industrial company. XRF's core risk is cyclical: roughly 70% of revenue flows from mining-related activity, meaning a commodity price downturn or mining capex pullback will impact results. I've constructed two complementary analyses to size these risks.

Earnings at Risk (EaR)

EaR quantifies the maximum decline in annual NPAT at a specified confidence level, under plausible adverse scenarios. I use a scenario-based approach for XRF given its limited public trading history at the current scale.

1-Year EaR at 95% Confidence

A$3.1M

Expected NPAT of ~A$10.6M could fall to A$7.5M or below in an adverse mining cycle.

Stress Scenario	Revenue Impact	NPAT Impact (A$M)	NPAT Under Stress	EaR vs Expected
Mining capex downturn (−15% revenue)	−A$9.3M	−A$2.5M	A$8.1M	A$2.5M
Gross margin compression (−5pp GPs)	—	−A$2.2M	A$8.4M	A$2.2M
AUD appreciation (AUD+10%)	−A$2.0M	−A$0.7M	A$9.9M	A$0.7M
PGM price collapse (−30% precious metals)	−A$6.4M	−A$1.8M	A$8.8M	A$1.8M
Combined stress (revenue −15%, margin −3pp)	−A$9.3M	−A$3.1M	A$7.5M	A$3.1M

Commentary: The combined stress scenario — where a mining downturn coincides with modest margin compression — represents the most plausible adverse outcome. NPAT of A$7.5M under this scenario still represents solid profitability; the business doesn't break. The EaR of A$3.1M is about 29% of expected NPAT, which is meaningful but not alarming for a mining-services business. Critically, XRF's consumables segment (~29% of revenue) provides a degree of earnings resilience — customers continue to process samples even through mild slowdowns, because mines don't shut immediately. The company's three-segment structure provides natural diversification of EaR across the mining value chain.

Economic Capital (EC)

For a non-financial company, economic capital analysis assesses whether the equity buffer is sufficient to absorb unexpected losses at a high confidence level. This is particularly relevant here given XRF's A$15.8M of goodwill (from historical acquisitions) which could be subject to impairment if conditions deteriorate.

Economic Capital Coverage Ratio

3.1×

Tangible equity + net cash (A$53.6M) vs EC requirement (A$17.2M). Strongly capitalised.

EC Component	Estimate (A$M)	Basis
Unexpected earnings loss (99%, 2× annual σ)	~4.0	2× SD of historical annual NPAT (~A$2.0M)
Goodwill impairment risk buffer	~8.0	50% haircut on A$15.8M goodwill (conservative)
Inventory obsolescence buffer	~3.6	20% of A$17.9M inventory (deterioration scenario)
Receivables default buffer	~1.3	15% of A$8.96M trade receivables
Operational contingency	~0.3	Regulatory, litigation, environmental tail
Total EC Requirement (est.)	~17.2	99th percentile confidence
Tangible Equity (equity − goodwill − intangibles)	42.1	A$61.4M − A$17.5M intangibles − A$1.75M other
Net Cash	9.7	Cash A$12.1M − Debt A$2.4M
Available Equity Capital	53.6	Tangible equity + net cash

Commentary: XRF is extremely well capitalised relative to its risk profile. Available capital of A$53.6M covers the EC requirement ~3.1× — meaning the business could absorb a very severe adverse scenario (goodwill impairment, inventory write-down, earnings shock simultaneously) and still emerge solvent with substantial buffer remaining. The credit model confirms this: with an implied rating of AA and a probability of default of just 0.03%, XRF's financial resilience is best-in-class for its peer group. The key risk is not financial distress — it is valuation. A well-capitalised business priced at a premium to intrinsic value still represents risk for equity investors if growth disappoints.

The SmartRatios credit model score of 98/100 (with Growth & Stability at 99/100, Liquidity at 91/100, and Coverage at 84/100) independently validates the financial strength assessment. This is an exceptional small-cap balance sheet.

Section 9: Risk Considerations

Mining cycle exposure. Roughly 70% of XRF's revenue is tied to mining activity — exploration, production, and capex. A sustained commodity price downturn or mining sector contraction would reduce sample volumes and machine orders. The FY2025 revenue decline of 1% vs FY2024 is an early hint that the post-COVID mining supercycle has moderated. There's no indication of structural decline, but the easy growth phase may have passed.

Precious metals price risk. The Precious Metals segment uses platinum-group metals (PGMs) as raw material inputs. PGM prices are volatile and correlated to both auto-sector demand (catalytic converters) and mining activity. A spike in PGM input costs that XRF cannot pass through would compress segment margins. Historically the company has managed this well, but it's a real input cost risk.

Customer concentration and geographic risk. Australia represents ~67% of revenue. While Canadian and European operations provide diversification, a sharp contraction in Australian mining activity (e.g., an iron ore price crash) would have outsized impact. XRF's strategy to grow international share is the right response, but execution takes time.

Key-person risk and governance. For a company of this size, management continuity matters. The Chairman and some directors have served for many years. Board refreshment and succession planning in management are worth monitoring, particularly given the insider selling pattern noted in the Red Flags section.

Valuation risk. At A$2.06 and 27.7× P/E, XRF is priced for continued execution. If growth stalls — as it did in FY2025 — the market re-rating could be swift. The FCF/EV of 3.6% provides minimal yield support below current prices.

Section 10: Analyst Consensus

XRF Scientific has limited sell-side coverage given its small-cap status (~A$295M market cap). The credit model text mining model score of 69/100 reflects moderate news sentiment, with Reuters News scoring 17/100 — suggesting some negative press flow. Research sentiment scores at 97/100, suggesting the available research is broadly positive. No formal consensus price targets or rating breakdowns were available in the data provided.

The absence of major institutional coverage is a double-edged sword. It means XRF potentially trades with less analyst-driven momentum but also that meaningful new institutional discovery could re-rate the stock over time. For a business with XRF's quality metrics, increased institutional attention is a plausible catalyst.

1. What Does XRF Scientific Do?

XRF Scientific makes the equipment, supplies, and specialist labware that mining laboratories use to test rock samples. When a mining company wants to know what's in a piece of ore — gold, iron, copper — they typically crush it, mix it with chemicals called fluxes, melt it into a glass bead in a platinum crucible, and then run it through an analyser. XRF Scientific sells the flux, the crucibles, the melting machines, and the platinum labware that make this process work. It's a picks-and-shovels business serving the mining industry rather than mining itself.

2. How Has the Business Been Performing?

Very well, over a sustained period. Revenue has effectively doubled in four years — from A$31M in the year to June 2021, to over A$62M on the most recent 12 months. Profits have grown even faster, because the company has been able to charge more for what it sells while keeping costs under control. For every A$1 of revenue today, XRF keeps about 17 cents as profit — up from 16 cents four years ago. The business generates strong cash and pays a growing dividend. The balance sheet is essentially debt-free, with A$12M of cash and only A$2.4M of borrowings. One minor concern: revenue was flat in the last full financial year (FY2025 vs FY2024), hinting that the post-COVID mining boom is moderating.

3. What Is It Actually Worth?

Based on my analysis, I estimate XRF's intrinsic value at roughly A$1.25 per share in a base case, rising to A$1.94 in an optimistic scenario. The current share price of A$2.06 sits above both — meaning even in a good scenario, you're paying more than the business appears to be worth today based on its current cash flows. The market is clearly betting that the business will grow significantly over the next decade and beyond, which is a reasonable expectation given its track record, but it leaves little room for disappointment.

4. The Savings Account Test

Think of buying the entire business for A$284.9M (its enterprise value). In the last 12 months, XRF generated A$10.4M in free cash flow — money left over after running and investing in the business. That's a 3.6% "interest rate" on your A$285M "deposit." A standard term deposit today pays around 5.0%. So you'd actually earn more in interest parking the same money in a bank term deposit than you'd earn in cash flow buying XRF at today's price. This doesn't make XRF a bad business — it's a great business — but it means you're paying a growth premium, and that premium only makes sense if the growth comes through.

5. Are There Any Red Flags?

One clear flag: a director, David Brown, sold 1 million shares in May 2024 and another million in September 2025. That's notable selling when the stock was trading well below today's price. On the positive side, Managing Director Stazzonelli has been buying on the market, which is reassuring. The biggest structural concern is governance — small board, long-tenured members. Otherwise, the financial controls, cash generation, and credit quality are excellent. The company has an implied credit rating of AA with a 0.03% probability of default — that's exceptional for a small Australian company. Verdict: CAUTION (1 flag, 3 watches) — solid company, worth monitoring the insider selling.

6. Bottom Line

XRF Scientific is one of the genuinely high-quality small-cap businesses on the ASX. The financials are strong, the business model is resilient, and the management team has compounded earnings impressively. The problem is price: at A$2.06, the shares are trading above my highest credible valuation scenario. You're paying for perfection. The risk isn't that XRF falls apart — it won't. The risk is that growth moderates (as it did in FY2025) and the market re-rates the stock toward its intrinsic value, which could mean 20–40% lower. I'd put this on the watchlist, wait for a pullback toward A$1.25–1.50, and revisit then.